Dear Colleagues,

I am currently in the process of negotiating a contract with Aventis
Pharmaceuticals, Inc.  This is a pre-clinical, investigator initiated
study.  The problem, as usual, deals with the IP language.  If you have
worked with Aventis recently, your insights would be appreciated.

Thanks,
Dan Christmus

Daniel L. Christmus
Sponsored Program Administrator
(803) 777-7093
(803) 777-4136 - fax

======================================================================
 Instructions on how to use the RESADM-L Mailing List, including
 subscription information and a web-searchable archive, are available
 via our web site at http://www.hrinet.org (click on "Listserv Lists")
======================================================================